Skip to main content
Betta Pharmaceuticals Co.,Ltd logo

Betta Pharmaceuticals Co.,Ltd — Investor Relations & Filings

Ticker · 300558 ISIN · CNE100002DD9 LEI · 8368009YF4Y6NC7HVB09 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,654 across all filing types
Latest filing 2022-04-12 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300558

About Betta Pharmaceuticals Co.,Ltd

https://www.bettapharma.com

Betta Pharmaceuticals Co.,Ltd. focuses on the research, development, and commercialization of innovative oncology medications. The organization specializes in targeted therapies, particularly for the treatment of lung cancer and other solid tumors. Its portfolio includes Icotinib, a small-molecule EGFR tyrosine kinase inhibitor, and Ensartinib, an ALK inhibitor designed for non-small cell lung cancer. The company operates a comprehensive R&D infrastructure dedicated to molecular biology, medicinal chemistry, and clinical development. By prioritizing precision medicine, the firm aims to deliver high-quality therapeutic solutions that address complex oncological challenges. Its pipeline encompasses a diverse range of candidates, including small molecules and biologics, aimed at improving patient outcomes through advanced scientific innovation.

Recent filings

Filing Released Lang Actions
关于盐酸恩沙替尼胶囊术后辅助治疗适应症获得临床试验批准通知书的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement from a pharmaceutical company about receiving clinical trial approval from the National Medical Products Administration (NMPA) for a new indication of a drug. It details the approval notice, the drug's background, and the impact on the company. The document is short (1379 characters) and does not contain financial data, earnings, or detailed financial reports. It is an official regulatory announcement about clinical trial approval, not a financial report or management discussion. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2022-04-12 Chinese
关于续聘2022年度会计师事务所的公告
Audit Report / Information Classification · 95% confidence The document is an announcement by 贝达药业股份有限公司 regarding the reappointment of the accounting firm 立信会计师事务所 as the company's auditor for the year 2022. It details the background, qualifications, and integrity of the accounting firm, the audit fees, and the approval process by the board and audit committee. The document does not contain actual financial statements or audit results but is a formal announcement of the intention to reappoint the auditor, pending shareholder approval. The document length is 4319 characters, which is relatively short and consistent with an announcement rather than a full audit report. Therefore, this document is best classified as an Audit Report / Information (AR) type, as it relates to audit information but is not a full annual report or financial statement. However, since it is primarily an announcement of auditor reappointment and related information, it fits the Audit Report / Information category rather than a full Annual Report (10-K) or Regulatory Filing (RNS). FY 2022
2022-04-06 Chinese
关于公司及子公司申请综合融资额度及为融资额度内融资提供担保的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement from 贝达药业股份有限公司 regarding the company's and its subsidiaries' application for a comprehensive financing quota and provision of guarantees within that quota. It includes specifics about the financing amount, the board meeting resolutions approving the financing and guarantees, descriptions of the subsidiaries involved, their financial data as of 2021, and the board's opinions on the matter. The document is not a financial report like an annual or interim report, nor is it a call transcript or earnings release. It is a formal announcement about financing activities and guarantees related to capital structure and funding. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length is sufficient and contains substantive content about financing and guarantees, not merely a brief notice or regulatory filing. Confidence is high due to the clear focus on financing and guarantees.
2022-04-06 Chinese
关于使用闲置募集资金进行现金管理的公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement by Betta Pharmaceuticals Co., Ltd. regarding the use of idle raised funds for cash management. It details the board and supervisory committee approvals, investment purpose, amount, duration, risk control measures, and compliance with regulatory requirements. The document does not contain actual financial statements or detailed financial results but rather informs shareholders and the public about the company's plan and approval to use idle raised funds for short-term bank wealth management products. It is a regulatory announcement about financing fund usage and management, not a full financial report or earnings release. The document length is 4158 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2022-04-06 Chinese
2021年度独立董事述职报告（赵骏）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's Annual Report" for the year 2021 of Betta Pharmaceuticals Co., Ltd. It details the independent director's attendance at board meetings, committees, shareholder meetings, independent opinions on various company matters, on-site investigations, and efforts to protect investor rights. The content focuses on governance, oversight, and compliance activities by the independent director rather than financial results or audit opinions. The document length is 4384 characters, which is relatively short and reads like a formal report or statement by an independent director about their duties and activities during the year. This type of document is best classified under Board/Management Information (MANG) as it relates to management and board-level disclosures about director activities and governance, rather than an annual report, audit report, or other financial filings.
2022-04-06 Chinese
2021年年度财务报告
Annual Report Classification · 100% confidence The document is titled as the 2021 annual financial report of 贝达药业股份有限公司 (Betta Pharmaceuticals Co., Ltd.) and contains detailed audited financial statements including consolidated and parent company balance sheets, profit and loss statements, cash flow statements, and notes. It includes an audit report with an unqualified opinion from a registered accounting firm dated April 1, 2022. The content is comprehensive, covering the full fiscal year 2021, with detailed financial data and management responsibilities. This matches the definition of an Annual Report (10-K) which covers the company's yearly activity and full financial performance. The document length is substantial (15,000 characters), and it is not merely an announcement or certification. Therefore, the correct classification is Annual Report (10-K). FY 2021
2022-04-06 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.